Inhibitors of enzymes involved in carbohydrate digestion may be a potential option for glycemic control in Diabetes Mellitus. This study aimed to evaluate the effect of the trypsin inhibitor isolated from tamarind seed (Tamarindus indica L.) (TTI) on α-amylase. After confirmation of the obtaining and characterization of the TTI, the in vitro inhibitory activity of the TTI against α-amylase was analyzed. The interaction of the modeled structures’ theoretical TTI (TTIp 56/287) and five of its derived peptides with α-amylase was also evaluated in silico using Docking and Molecular Dynamics, and their functional properties were examined. The Interaction Potential Energy (IPE) and the main interactions of the peptide-α-amylase complex were described using three-dimensional representations. TTI presented 100% antitryptic activity and a molecular mass of approximately 21 kDa. In vitro, inhibition of α-amylase was higher than 37%. These results were corroborated by computational analyses, which demonstrated strong interaction between the TTIp 56/287 complex and its peptides with the enzyme. The Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF) analyses showed good stability. IPE was −705.08 kJ/mol for DTVHDTDGQVPL and −584.11 kJ/mol for TIAPACAPKPAR. Electrostatic interactions stand out, especially the salt bridge, between the main residues that interacted in the complexes (DTVHDTDGQVPL, TIAPACAPKPAR, and TVSQTPIDIPIGLPVR). Additionally, the bioactive potential predicted two candidates with good stability, a long half-life, and bioactivity in an intestinal simulation environment. This is the first report of tamarind trypsin inhibitor or its peptides inhibiting α-amylase. Thus, the amino acid sequences DTVHDTDGQVPL and TIAPACAPKPAR were revealed as candidates that could be tested for action against α-amylase and possibly for glycemic control.

Sleep disorders, such as insomnia and narcolepsy, significantly impact quality of life. They are often associated with long-term health consequences, including cardiovascular disease, immune dysfunction, and cognitive impairment. While traditional treatments, such as sedatives and hypnotics, can be effective, they are limited by issues of tolerance and dependence. The orexinergic system, particularly the orexin 1 receptor (OXR1), has emerged as a promising therapeutic target due to its central role in regulating sleep–wake cycles. In this study, we investigate the molecular interactions of three OXR1 antagonists—daridorexant, lemborexant, and suvorexant—using an integrated computational approach combining molecular dynamics (MD) simulations, density functional theory (DFT) calculations, and the molecular fractionation with conjugate caps (MFCC) methodology. The MFCC approach enabled the precise quantification of interaction energies between ligands and key receptor residues, providing detailed insights into the contributions of specific amino acids to binding stability. Our results reveal that residues such as GLU204, HIS216, and ASN318 play critical roles in stabilizing ligand–receptor interactions, with a marked decrease in binding energy magnitude as dielectric constants increase. Daridorexant exhibited the strongest interaction energy, driven by hydrogen bonds and hydrophobic contacts, while lemborexant and suvorexant showed distinct stabilization patterns mediated by hydrophobic interactions. These findings provide a robust molecular basis for the rational design of next-generation OXR1 antagonists with improved efficacy and safety profiles. By elucidating drug–receptor interactions at the atomic level, this research underscores the impact of integrated computational approaches in drug discovery. It supports the development of precise targeted therapies for sleep disorders.

A detailed understanding of ligand recognition and binding at the orexin receptor 2 (OXR2) is essential for the rational design of selective therapeutics for sleep and neuropsychiatric disorders.